NPS Pharmaceuticals to Present at UBS Global Life Sciences Conference

• Press Release
• Source: NPS Pharmaceuticals, Inc.
• On 4:21 pm EDT, Monday September 14, 2009

BEDMINSTER, N.J.--(BUSINESS WIRE)--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP - News) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the UBS Global Life Sciences Conference in New York on Monday, September 21 at 8:30 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the NPS website at http://www.npsp.com.

Related Quotes

Symbol	Price	Change
NPSP	3.14	+0.02

{"s" : "npsp","k" : "c10,l10,p20,t10","o" : "","j" : ""}

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently conducting two Phase 3 registration studies. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX™ in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and in preclinical development for gastrointestinal mucositis and other pediatric indications. NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Kyowa Kirin, Nycomed, and Ortho-McNeil-Janssen Pharmaceuticals. Additional information is available at http://www.npsp.com.

NPS Pharmaceuticals, Inc.
Gail Brophy, 908-450-5335